<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164059</url>
  </required_header>
  <id_info>
    <org_study_id>NeSSy_200901</org_study_id>
    <secondary_id>2009-010966-47</secondary_id>
    <nct_id>NCT01164059</nct_id>
  </id_info>
  <brief_title>Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia</brief_title>
  <acronym>NeSSy</acronym>
  <official_title>Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bremen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bremen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the efficacy and drug tolerability of two strategies for
      the treatment of schizophrenia. The two strategies consist of utilizing, on the one hand, a
      conventional antipsychotic like haloperidol or flupentixol and, on the other hand, a newer
      antipsychotic compound like olanzapine, quetiapine or aripiprazole in patients with
      schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is agreement in the psychiatry community that the so-called atypical antipsychotics
      should be considered first choice in the treatment of schizophrenic disorders. However, the
      general superiority of these newer antipsychotic drugs over the older conventional drugs
      could not be clearly demonstrated in recent controlled clinical trials. The discrepancy
      between every day's clinical perception and the results of clinical trials raises the
      question whether the studies performed so far employed the adequate methodological approach
      to represent the daily practice situation which is characterized by a wide variety of
      duration and type of the schizophrenic disorder, concomitant diseases, and medications.
      Moreover, some studies might not have been focused adequately on patient-relevant outcome
      variables.

      The present study project is designed to answer these open questions. The innovative
      character of the study design is

        1. that different neuroleptic strategies will be compared rather than single antipsychotic
           drugs, using

        2. an enhanced biometric design, that provides a choice of treatment with respect to the
           individual patient though the trial as such is randomised controlled and double blind;

        3. that clinically relevant endpoints such as quality of life will be the primary
           variables, and

        4. inclusion and exclusion criteria lead to a study population representing clinical every
           day practice as near as possible.

      Another innovatory procedure is that serum levels of the study drugs will be recorded twice
      during the study. The authors hope that their design might yield transfer effects for other
      clinical trials facing similar problems.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contentment with treatment: Patient (SF-36)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Contentment with treatment: Psychiatrist (CGI)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subscores of SF-36</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective wellbeing under neuroleptic treatment scale (SWN-K)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>atypical antipsychotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine, Quetiapine, or Aripiprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>typical antipsychotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Haloperidol or Flupentixol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine 10, 15, or 20 mg / day</description>
    <arm_group_label>atypical antipsychotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flupentixol</intervention_name>
    <description>Flupentixol 6, 9, or 12 mg / day</description>
    <arm_group_label>typical antipsychotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Quetiapine 400, 600, or 800 mg / day</description>
    <arm_group_label>atypical antipsychotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Aripiprazole 10, 15, or 20 mg / day</description>
    <arm_group_label>atypical antipsychotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Haloperidol 3, 4.5, or 6 mg / day</description>
    <arm_group_label>typical antipsychotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia

          -  age 18-65 years

          -  necessity to establish new or change antipsychotic treatment due to unsatisfying
             results or side effects

          -  written informed consent

        Exclusion Criteria (amongst others):

          -  Known or suspected hypersensitivity to olanzapine, quetiapine, aripiprazole,
             flupentixol or haloperidol

          -  Acute suicidal tendency

          -  &quot;Einwilligungsvorbehalt (BGB)&quot; or &quot;Unterbringung (PsychKG)&quot;

          -  Epilepsy

          -  Organic psychosis

          -  Parkinson Disease

          -  Dementia

          -  History of malignant neuroleptic syndrome

          -  QTc interval ≥ 0.5s / history of congenital QTc prolongation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Angermünde</name>
      <address>
        <city>Angermünde</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karl-Jaspers-Klinik</name>
      <address>
        <city>Bad Zwischenahn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LWL-Universitätsklinik Bochum der Ruhr-Universität</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Ost gGmbH</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheinische Kliniken Düsseldorf der Heinrich-Heine-Universität</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus Eisenhüttenstadt GmbH</name>
      <address>
        <city>Eisenhüttenstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privat-Nerven-Klinik Dr. med. Kurt Fontheim</name>
      <address>
        <city>Liebenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dietrich-Bonhoeffer-Klinik Neubrandenburg</name>
      <address>
        <city>Neubrandenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruppiner Kliniken</name>
      <address>
        <city>Neuruppin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ernst von Bergmann Klinikum</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinik Rüdersdorf</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Taufkirchen</name>
      <address>
        <city>Taufkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>June 19, 2015</last_update_submitted>
  <last_update_submitted_qc>June 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bremen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Eckart Rüther</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>atypical antipsychotic drugs</keyword>
  <keyword>conventional antipsychotic drugs</keyword>
  <keyword>olanzapine</keyword>
  <keyword>quetiapine</keyword>
  <keyword>aripiprazole</keyword>
  <keyword>haloperidol</keyword>
  <keyword>flupentixol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Flupenthixol</mesh_term>
    <mesh_term>Flupenthixol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

